keyword
MENU ▼
Read by QxMD icon Read
search

Vortioxetine

keyword
https://www.readbyqxmd.com/read/29792585/assessment-in-work-productivity-and-the-relationship-with-cognitive-symptoms-atworc-primary-analysis-from-a-canadian-open-label-study-of-vortioxetine-in-patients-with-major-depressive-disorder-mdd
#1
Pratap Chokka, Joanna Bougie, Emmanouil Rampakakis, Jean Proulx
OBJECTIVE: The Assessment in Work Productivity and the Relationship with Cognitive Symptoms (AtWoRC) study aimed to assess the association between cognitive symptoms and work productivity in gainfully employed patients receiving vortioxetine for a major depressive episode (MDE). METHODS: Patients diagnosed with major depressive disorder (MDD) and treated with vortioxetine independently of study enrollment were assessed over 52 weeks at visits that emulated a real-life setting...
May 24, 2018: CNS Spectrums
https://www.readbyqxmd.com/read/29768955/results-of-a-real-world-study-on-vortioxetine-in-patients-with-major-depressive-disorder-in-south-east-asia-revida
#2
Cheuk Ngen Chin, Azhar Zain, Solaphat Hemrungrojn, Eng Khean Ung, Patanon Kwansanit, Koon Choong Au Yong, Marvin Swee Woon Chong, Chalowat Inpa, Teck Hoe Yen, Boon Beng David Yeoh, Liam Kai Tay, Carmina Bernardo, Lionel Chee-Chong Lim, Chin Hong Yap, Calvin Fones, Ashwini Nayak, Lars Nelleman
OBJECTIVE: The REVIDA study aimed to assess the evolution of major depression symptoms in South East Asian (SEA) patients treated with vortioxetine for major depression in real-world clinical practice. METHODS: This non-interventional study was conducted from Aug 2016 to Apr 2017. A total of 138 patients (aged 18-65 years) with an active episode of major depression were recruited from Malaysia, Philippines, Singapore, and Thailand. Vortioxetine was initiated on the first visit and patients were followed for 3 months...
May 17, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29760763/an-open-label-flexible-dose-adaptive-study-evaluating-the-efficacy-of-vortioxetine-in-subjects-with-panic-disorder
#3
Anish Shah, Joanne Northcutt
Background: Despite the current treatments available for panic disorder (PD), as many as one-third of patients have persistent and treatment-resistant panic attacks. Vortioxetine is an approved medicine for major depressive disorder and has been shown to have anxiolytic properties. The purpose of this study was to evaluate its efficacy and safety in an adult population with a diagnosis of PD. Methods: The study design was open label with flexible dose strategies (5, 10, or 20 mg) with a treatment period of 10 weeks...
2018: Annals of General Psychiatry
https://www.readbyqxmd.com/read/29726758/pharmacotherapy-for-the-treatment-of-depression-in-patients-with-alzheimer-s-disease-a-treatment-resistant-depressive-disorder
#4
Madia Lozupone, Maddalena La Montagna, Francesca D'Urso, Carla Piccininni, Rodolfo Sardone, Vittorio Dibello, Gianluigi Giannelli, Vincenzo Solfrizzi, Antonio Greco, Antonio Daniele, Nicola Quaranta, Davide Seripa, Antonello Bellomo, Giancarlo Logroscino, Francesco Panza
Pharmacotherapy for the treatment of depressive disorders in Alzheimer's Disease (AD) represents a clinical challenge. pharmacological options are often attempted after a period of watchful waiting (8-12 weeks). monoaminergic antidepressant drugs have shown only modest or null clinical benefits, maybe because the etiology of depressive symptoms in ad patients is fundamentally different from that of nondemented subjects. Areas covered: The following article looks at the selective serotonin reuptake inhibitor sertraline, which is one of the most frequently studied antidepressant medications in randomized controlled trials (RCTs)...
May 4, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29720810/recovery-of-visual-scotomas-by-vortioxetine-in-a-patient-with-symptomatic-occipital-lobe-epilepsy
#5
Halil Onder, Akin Coskun, M Tugba Goksungur
No abstract text is available yet for this article.
January 2018: Annals of Indian Academy of Neurology
https://www.readbyqxmd.com/read/29718600/relative-efficacy-and-acceptability-of-antidepressant-drugs-in-adults-with-major-depressive-disorder-commentary-on-a-network-meta-analysis
#6
Chittaranjan Andrade
A large number of antidepressant drugs are available across the world. All have been compared against placebo, and many have been compared with some but not all other antidepressants. There is therefore little information about a hierarchy of the efficacy and acceptability of these drugs. About 9 years ago, a network meta-analysis attempted to rank the efficacy and acceptability of 12 newer antidepressant drugs in adults with major depressive disorder. Very recently, this network meta-analysis was updated to include 21 antidepressant drugs, most of which were introduced during the 1980s and afterward...
March 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29689693/vortioxetine-improves-symptomatic-and-functional-outcomes-in-major-depressive-disorder-a-novel-dual-outcome-measure-in-depressive-disorders
#7
Michael Cronquist Christensen, Henrik Loft, Roger S McIntyre
BACKGROUND: With symptomatic remission and functional recovery as the overarching therapeutic objectives of antidepressant therapy, composite endpoint measures that conjointly consider both aspects of treatment are needed. This analysis evaluated the combined effect of vortioxetine on depressive symptoms and functional capacity in adults with MDD. METHODS: NCT01564862, a multinational, double-blind, placebo-controlled, duloxetine-referenced study, conducted between April 2012 and February 2014, in 602 adult outpatients (18-65 years) with moderate-to-severe MDD (Montgomery-Åsberg Depression Rating Scale (MADRS) ≥ 26), a major depressive episode of ≥ 3 months' duration, and self-reported cognitive symptoms were randomized to once-daily vortioxetine (10 or 20mg), duloxetine (60mg), or placebo for 8 weeks...
February 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29677603/the-comparative-evidence-basis-for-the-efficacy-of-second-generation-antidepressants-in-the-treatment-of-depression-in-the-us-a-bayesian-meta-analysis-of-food-and-drug-administration-reviews
#8
Rei Monden, Annelieke M Roest, Don van Ravenzwaaij, Eric-Jan Wagenmakers, Richard Morey, Klaas J Wardenaar, Peter de Jonge
BACKGROUND: Studies have shown similar efficacy of different antidepressants in the treatment of depression. METHOD: Data of phase-2 and -3 clinical-trials for 16 antidepressants (levomilnacipran, desvenlafaxine, duloxetine, venlafaxine, paroxetine, escitalopram, vortioxetine, mirtazapine, venlafaxine XR, sertraline, fluoxetine, citalopram, paroxetine CR, nefazodone, bupropion, vilazodone), approved by the FDA for the treatment of depression between 1987 and 2016, were extracted from the FDA reviews that were used to evaluate efficacy prior to marketing approval, which are less liable to reporting biases...
April 6, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29673132/the-effects-of-vortioxetine-on-cognitive-dysfunction-in-patients-with-inadequate-response-to-current-antidepressants-in-major-depressive-disorder-a-short-term-randomized-double-blind-exploratory-study-versus-escitalopram
#9
Eduard Vieta, Lasse B Sluth, Christina K Olsen
BACKGROUND: Major Depressive Disorder (MDD) is a heterogeneous disease characterized by emotional, physical and cognitive symptoms. This study explored the effects of vortioxetine versus escitalopram on outcomes of cognition, functioning and mood symptoms in depressed patients with inadequate response to current antidepressant treatment. METHODS: In this parallel-group, active-comparator study, adult patients (18-65 years, N = 101) with MDD, with inadequate response to current antidepressant monotherapy, were randomized 1:1 to 8 weeks' double-blind treatment with flexible doses (10-20mg/day) of either vortioxetine or escitalopram...
February 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29627920/advances-in-pharmacotherapy-of-late-life-depression
#10
REVIEW
John L Beyer, Kim G Johnson
This paper reviews recent research on late-life depression (LLD) pharmacotherapy, focusing on updated information for monotherapy and augmentation treatments. We then review new research on moderators of clinical response and how to use the information for improved efficacy. RECENT FINDINGS: A recent review shows that sertraline, paroxetine, and duloxetine were superior to placebo for the treatment of LLD. There is concern that paroxetine could have adverse outcomes in the geriatric population due to anticholinergic properties; however, studies show no increases in mortality, dementia risk, or cognitive measures...
April 7, 2018: Current Psychiatry Reports
https://www.readbyqxmd.com/read/29596146/vortioxetine-disposition-in-obesity-potential-implications-for-patient-safety
#11
David J Greenblatt, Jerold S Harmatz, Christina R Chow
BACKGROUND: Obesity and depression are common comorbid conditions. The objective of the study was to evaluate the effect of obesity on the pharmacokinetics of the serotonergic antidepressant vortioxetine. METHODS: Vortioxetine pharmacokinetics were evaluated in 16 otherwise healthy obese volunteers (mean weight, 119 kg; mean body mass index (BMI) 41.8 kg/m) and in 14 normal-weight subjects (mean weight, 68 kg; mean BMI, 23.0 kg/m) matched for age. All subjects received a single 5-mg oral dose of vortioxetine once daily for 29 days...
March 28, 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29593535/vortioxetine-improves-context-discrimination-in-mice-through-a-neurogenesis-independent-mechanism
#12
Daniela Felice, Jean-Philippe Guilloux, Alan Pehrson, Yan Li, Indira Mendez-David, Alain M Gardier, Connie Sanchez, Denis J David
Major Depressive Disorders (MDD) patients may exhibit cognitive deficits and it is currently unclear to which degree treatment with antidepressants may affect cognitive function. Preclinical and clinical observations showed that vortioxetine (VORT, an antidepressant with multimodal activity), presents beneficial effects on aspects of cognitive function. In addition, VORT treatment increases adult hippocampal neurogenesis (AHN) in rodents, a candidate mechanism for antidepressant activity. Pattern separation (PS) is the ability to discriminate between two similar contexts/events generating two distinct and non-overlapping representations...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29559911/vortioxetine-treatment-reverses-subchronic-pcp-treatment-induced-cognitive-impairments-a-potential-role-for-serotonin-receptor-mediated-regulation-of-gaba-neurotransmission
#13
Alan L Pehrson, Christian S Pedersen, Kirstine Sloth Tølbøl, Connie Sanchez
Major depressive disorder (MDD) is associated with cognitive impairments that may contribute to poor functional outcomes. Clinical data suggests that the multimodal antidepressant vortioxetine attenuates some cognitive impairments in MDD patients, but the mechanistic basis for these improvements is unclear. One theory suggests that vortioxetine improves cognition by suppressing γ-amino butyric acid (GABA)ergic neurotransmission, thereby increasing glutamatergic activation. Vortioxetine's effects on cognition, GABA and glutamate neurotransmission have been supported in separate experiments, but no empirical work has directly connected vortioxetine's cognitive effects to those on GABA and glutamate neurotransmission...
2018: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29554497/efficacy-and-tolerability-of-vortioxetine-versus-agomelatine-categorized-by-previous-treatment-in-patients-with-major-depressive-disorder-switched-after-an-inadequate-response
#14
George I Papakostas, Rebecca Z Nielsen, Marianne Dragheim, Brigitte Tonnoir
This study aimed to evaluate if efficacy and tolerability of switching to vortioxetine is independent of previous SSRI or SNRI treatment in patients who had been inadequately treated for their current major depressive episode. Patients from a double-blind, 12-week comparator study were randomized (1:1) to vortioxetine (10-20 mg/day) or agomelatine (25-50 mg/day). The pre-defined primary efficacy endpoint was change from baseline to week 8 in MADRS total score analyzed by MMRM. An ANCOVA-LOCF was conducted as a sensitivity analysis...
June 2018: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29546401/a-subgroup-analysis-of-the-impact-of-vortioxetine-on-functional-capacity-as-measured-by-upsa-in-patients-with-major-depressive-disorder-and-subjective-cognitive-dysfunction
#15
Richard S E Keefe, George Nomikos, Wei Zhong, Michael Cronquist Christensen, William Jacobson
Background: We evaluated vortioxetine's effects on functional capacity in demographic and clinical subgroups of patients with major depressive disorder. Methods: This was an exploratory analysis of the CONNECT study (NCT01564862) that evaluated changes in functional capacity using University of California San Diego Performance-based Skills Assessment data, categorized by sex, age, education, employment status, and baseline disease severity (Montgomery-Åsberg Depression Rating Scale, Clinical Global Impressions-Severity of Illness)...
May 1, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29514282/a-critical-role-of-mitochondria-in-bdnf-associated-synaptic-plasticity-after-one-week-vortioxetine-treatment
#16
Fenghua Chen, Jibrin Danladi, Maryam Ardalan, Betina Elfving, Heidi K Müller, Gregers Wegener, Connie Sanchez, Jens R Nyengaard
Background: Preclinical studies have indicated that antidepressant effect of vortioxetine involves increased synaptic plasticity and promotion of spine maturation. Mitochondria dysfunction may contribute to the pathophysiological basis of major depressive disorder. Taking into consideration that vortioxetine increases spine number and dendritic branching in hippocampus CA1 faster than fluoxetine, we hypothesize that new spines induced by vortioxetine can rapidly form functional synapses by mitochondrial support, accompanied by increased brain-derived neurotrophic factor (BDNF)-signaling...
March 5, 2018: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29477251/comparative-efficacy-and-acceptability-of-21-antidepressant-drugs-for-the-acute-treatment-of-adults-with-major-depressive-disorder-a-systematic-review-and-network-meta-analysis
#17
Andrea Cipriani, Toshi A Furukawa, Georgia Salanti, Anna Chaimani, Lauren Z Atkinson, Yusuke Ogawa, Stefan Leucht, Henricus G Ruhe, Erick H Turner, Julian P T Higgins, Matthias Egger, Nozomi Takeshima, Yu Hayasaka, Hissei Imai, Kiyomi Shinohara, Aran Tajika, John P A Ioannidis, John R Geddes
BACKGROUND: Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide in adults. Pharmacological and non-pharmacological treatments are available; however, because of inadequate resources, antidepressants are used more frequently than psychological interventions. Prescription of these agents should be informed by the best available evidence. Therefore, we aimed to update and expand our previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder...
April 7, 2018: Lancet
https://www.readbyqxmd.com/read/29382958/effective-vortioxetine-dose-varies-with-extent-of-antidepressant-use-across-countries
#18
Cuneyt Tegin, Gulay Tegin, Rif S El-Mallakh
Objective: One of the possible explanations for the antidepressant resistance is tolerance to the effect of increasing synaptic serotonin. Vortioxetine is thought to work through a combination of two pharmacological modes of action: serotonin reuptake inhibition and modification of serotonin receptor activity, in a dose-dependent manner. This mechanism of action allows for examination of the hypothesis that antidepressant non-response may be due to exposure to persistently elevated synaptic amine levels...
January 15, 2018: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/29344340/assessment-and-management-of-sexual-dysfunction-in-the-context-of-depression
#19
REVIEW
Pratap R Chokka, Jeffrey R Hankey
Sexual dysfunction (SD) is pervasive and underreported, and its effects on quality of life are underestimated. Due in part to its bidirectional relationship with depression, SD can be difficult to diagnose; it is also a common side effect of many antidepressants, leading to treatment noncompliance. While physicians often count on patients to spontaneously report SD, treatment is optimized when the clinician instead performs a thorough assessment of sexual functioning before and during drug therapy using a standardized questionnaire such as the Arizona Sexual Experiences Scale (ASEX)...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29331703/the-effects-of-vortioxetine-on-cognitive-performance-in-working-patients-with-major-depressive-disorder-a-short-term-randomized-double-blind-exploratory-study
#20
Bernhard T Baune, Lasse B Sluth, Christina K Olsen
BACKGROUND: Major Depressive Disorder (MDD) is a complex disease characterized by emotional, physical and cognitive symptoms. We explored the efficacy of vortioxetine versus placebo on outcomes of cognition, functioning and mood symptoms in working patients with depression, using paroxetine as an active reference. METHODS: Gainfully employed patients (18-65 years, N = 152) with MDD were randomized 1:1:1 to 8 weeks' double-blind, parallel treatment either with vortioxetine (10mg/day) or paroxetine (20mg/day), or with placebo...
March 15, 2018: Journal of Affective Disorders
keyword
keyword
22035
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"